December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

240.47 +5.20 (+2.21%)
Streaming Delayed Price Updated: 3:19 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns
As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading... 
Via MarketMinute
Topics Artificial Intelligence Bonds Earnings
News headline image
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
From Johnson & Johnson
Via Business Wire
News headline image
Blue-Chip Bull Run: Dow Jones Eyes 50,000 Milestone Amidst 2026 Technical Pivot
As the final bells of 2025 ring across the floor of the New York Stock Exchange, the Dow Jones Industrial Average (DJI) stands at a historic crossroads. After a year defined by a resilient "soft... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot
As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit ↗
The company said that the drug did not achieve the “high-bar””efficacy targets in a planned interim analysis. 
Via Stocktwits
News headline image
Johnson &amp; Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss ↗
Johnson & Johnson's Phase 2b study for atopic dermatitis did not meet high-bar efficacy and was terminated early. 
Via Benzinga
News headline image
Baxter International (BAX) in 2025: A Deep Dive into the Transformation of a MedTech Giant
As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare... 
Via PredictStreet
Topics Economy Emissions Product Recall
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026
As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
This Dividend ETF Could Quietly Make You a Multimillionaire Over Time ↗
This ETF invests in stocks with proven wealth-creating capabilities. 
Via The Motley Fool
Topics ETFs
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025. 
Via Stocktwits
News headline image
Legal Seismic Shift: Johnson & Johnson Faces Record $1.5 Billion Talc Verdict as Bankruptcy Strategy Collapses
In a landmark ruling that has sent shockwaves through the corporate legal landscape, a Baltimore jury has ordered Johnson & Johnson (NYSE: JNJ) to pay a staggering $1.56 billion to a single plaintiff.... 
Via MarketMinute
Topics Bankruptcy Bonds Lawsuit
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
News headline image
The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years ↗
These low-risk dividend stocks have the potential to produce a more than 100% total return over the next decade. 
Via The Motley Fool
News headline image
Johnson &amp; Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim ↗
Baltimore jury awards $1.5 billion against Johnson & Johnson in record talc-asbestos mesothelioma verdict; company plans to appeal. 
Via Benzinga
News headline image
The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'
As the curtain closes on 2025, the global financial landscape is witnessing a seismic shift in corporate strategy. After two years of "wait-and-see" posturing dictated by high interest rates and... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment. 
Via Barchart.com
Topics ETFs
News headline image
Why a Minnesota Jury Ordered Johnson &amp; Johnson To Pay $65.5 Million in Damages ↗
Johnson & Johnson has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. 
Via Benzinga
News headline image
The 10% Shadow: Analyzing the Growing Risk of a 30% Market Correction in 2026
As 2025 draws to a close, a sobering forecast from Barron’s has sent ripples through the financial community, suggesting a 10% probability of a massive 30% stock market crash in 2026. While the broader... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Want $10,000 in Passive Income? This Vanguard ETF Could Be Your Ticket to Making It Happen. ↗
Investors would need to have over $330,000 invested in this Vanguard dividend ETF. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
FDA Approves J&amp;J&#39;s New 5-Minute Injection For Lung Cancer ↗
FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma treatment. 
Via Benzinga
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
The Yield Search: Why Retirees are Swapping Growth for Defense in a Shifting 2025 Market
As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable,... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Rate Cuts Make These 3 Income ETFs More Attractive Than Ever ↗
Via MarketBeat
Topics ETFs
News headline image
The Emotional Rollercoaster: How Fear and Greed Shape Investor Behavior in Market Downturns
The financial markets, often perceived as bastions of rational decision-making, are, in reality, deeply swayed by the powerful currents of human emotion. As the global economy navigates its inherent... 
Via MarketMinute
Topics Bonds Economy Supply Chain
News headline image
The Market's Shifting Sands: Investor Behavior Points to Risk-Off Pivot Amidst Year-End Selloff
The financial markets are currently experiencing a significant recalibration, with investor behavior data as of December 17, 2025, signaling a distinct "risk-off" posture despite underlying bullish... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Investors Rotate Out of Big Tech and AI: A Market Reassessment Underway
As late 2025 draws to a close, a significant recalibration is underway in global financial markets, with investors increasingly rotating capital away from the once-dominant Big Tech and Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.